Complete Filing Data
Scinai Immunotherapeutics Ltd. reported Research And Development Expense of $5.53 million for FY2024.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean Scinai Immunotherapeutics Ltd. did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income * | $4.8M | -$6.5M | -$5.8M | -$8.2M | -$4.5M | -$109.2M | -$87.7M | -$34.6M | -$9.2M | -$10.2M |
| Research And Development Expense | $5.5M | $5.2M | $5.8M | $3.2M | $51.5M | $68.6M | $71.9M | $18.8M | $7.8M | $7.9M |
| Selling General And Administrative Expense | $2.5M | $4.5M | $5.3M | $7.6M | $9.7M | $5.2M | $4.9M | $4.1M | $3.4M | |
| Operating Income Losses | -$11.2M | $7.3M | -$78.4M | -$77.1M | -$23.7M | -$11.9M | -$11.3M | |||
| Adjustments For Reconcile Profit Loss | $13.2M | -$53.5M | $35.5M | $12.6M | $22.2M | -$827.0K | $276.0K | |||
| General And Administrative Expense | $7.9M | $16.7M | $9.7M | $5.2M | ||||||
| Comprehensive Income Net Of Tax | $4.8M | -$6.2M | -$5.7M | -$8.2M | ||||||
| Operating Income Loss | -$8.6M | -$9.7M | -$11.1M | -$10.9M | ||||||
| Comprehensive Income | -$40.0M | -$4.5M | -$109.2M | -$87.7M | -$34.6M | -$9.2M | -$10.2M | |||
| Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax | $267.0K | $48.0K | $39.0K | |||||||
| Revenues | $658.0K | |||||||||
| Cost Of Revenue | $1.2M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q1 2023 | Q1 2022 |
|---|---|---|
| Net Income * | -$3.5M | -$2.5M |
| Research And Development Expense | $2.0M | $1.2M |
| Selling General And Administrative Expense | ||
| Operating Income Losses | ||
| Adjustments For Reconcile Profit Loss | ||
| General And Administrative Expense | $1.2M | $1.5M |
| Comprehensive Income Net Of Tax | -$3.4M | -$2.5M |
| Operating Income Loss | -$3.2M | -$2.6M |
| Comprehensive Income | ||
| Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax | $116.0K | -$34.0K |
| Revenues | ||
| Cost Of Revenue |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stockholders Equity * | $10.0M | -$4.6M | -$1.8M | $982.0K | -$15.0M | ||||||
| Cash And Cash Equivalents | $54.0M | $3.0M | $72.5M | $75.9M | $71.4M | $15.7M | $33.5M | $9.6M | |||
| Assets | $13.4M | $17.5M | $27.1M | $32.0M | $56.9M | $115.8M | $105.8M | $81.7M | $30.1M | ||
| Equity | $10.0M | -$4.6M | -$1.8M | $982.0K | -$15.0M | ||||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $2.1M | $5.0M | $14.2M | $17.5M | $3.1M | ||||||
| Total Cash Paid And Received | -$11.0K | -$43.0K | -$129.0K | $52.0K | -$60.0K | $35.0K | $5.0K | ||||
| Purchase Of Property Plant And Equipment Classified As Investing Activities | $138.0K | $6.1M | $7.4M | $23.7M | $4.5M | $20.0K | $34.0K | ||||
| Cash Flows From Used In Operating Activities | -$24.5M | -$72.5M | -$77.1M | -$57.2M | -$10.1M | -$9.7M | -$10.3M | ||||
| Cash Flows From Used In Investing Activities | -$116.0K | -$5.9M | -$7.2M | -$23.5M | $6.8M | -$7.8M | -$43.0K | ||||
| Adjustments For Decrease Increase In Trade And Other Receivables | $162.0K | -$548.0K | $309.0K | $3.0M | -$3.1M | $640.0K | -$744.0K | ||||
| Cash Flows From Used In Financing Activities | $21.8M | $13.7M | $85.2M | $84.3M | $61.8M | $33.8M | |||||
| Cash And Cash Equivalents At Carrying Value | $2.0M | $4.9M | $14.1M | $17.4M | |||||||
| Adjustments For Increase In Liability With Respect To Loans From Others | $910.0K | -$63.4M | $14.1M | $9.2M | |||||||
| Adjustment In Depreciation Of Property Plant And Equipment And Rightofuse Assets | $2.4M | $2.4M | $1.6M | $260.0K | $440.0K | ||||||
| Total Changes In Asset And Liability | -$4.5M | -$3.2M | $17.9M | $2.4M | $323.0K | ||||||
| Decrease Increase In Other Longterm Assets | $29.0K | $37.0K | $230.0K | $140.0K | -$402.0K | ||||||
| Adjustments For Increase Decrease In Employee Benefit Liabilities | $6.0K | $7.0K | -$1.0K | $7.0K | $7.0K | $7.0K | |||||
| Restricted Cash | $131.0K | $140.0K | $140.0K | $143.0K | |||||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | -$2.9M | -$9.2M | -$3.3M | $14.4M | |||||||
| Trade And Other Current Receivables | $1.0M | $1.2M | $656.0K | $965.0K | $3.9M | $815.0K | |||||
| Trade And Other Current Payables | $999.0K | $1.9M | $17.1M | $20.7M | $6.2M | $686.0K | |||||
| Retained Earnings | -$117.3M | -$324.8M | -$320.3M | -$211.1M | -$123.4M | -$88.9M | |||||
| Property Plant And Equipment | $38.5M | $39.6M | $35.0M | $28.2M | $5.5M | $1.4M | |||||
| Other Payables Current | $3.3M | $1.2M | $1.2M | $1.1M | $660.0K | $689.0K | |||||
| Noncurrent Liabilities | $69.1M | $7.3M | $161.8M | $115.3M | $18.6M | $3.1M | |||||
| Noncurrent Assets | $44.6M | $46.3M | $42.6M | $29.0M | $6.4M | $4.0M | |||||
| Equity And Liabilities | $32.0M | $56.9M | $115.8M | $105.8M | $81.7M | $30.1M | |||||
| Current Liabilities | $2.3M | $64.2M | $19.0M | $21.8M | $6.9M | $1.4M | |||||
| Current Assets | $55.0M | $10.6M | $73.1M | $76.8M | $75.3M | $26.1M | |||||
| Retained Earnings Accumulated Deficit | -$117.5M | -$122.3M | -$115.8M | -$110.0M | |||||||
| Property Plant And Equipment Net | $9.2M | $10.8M | $11.2M | $12.4M | |||||||
| Other Loans Payable Long Term | $260.0K | $19.4M | $20.1M | $27.2M | |||||||
| Operating Lease Right Of Use Asset | $1.9M | $1.2M | $1.5M | $1.8M | |||||||
| Operating Lease Liability Noncurrent | $1.4M | $797.0K | $1.1M | $1.4M | |||||||
| Liabilities Noncurrent | $1.7M | $20.3M | $26.5M | $28.6M | |||||||
| Liabilities Current | $1.8M | $1.8M | $2.3M | $2.4M | |||||||
| Liabilities And Stockholders Equity | $13.4M | $17.5M | $27.1M | $32.0M | |||||||
| Increase In Liability With Respect To Government Grants | -$14.8M | $169.0K | $4.3M | $10.3M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q1 2023 | Q1 2022 |
|---|---|---|
| Stockholders Equity * | -$4.8M | -$862.0K |
| Cash And Cash Equivalents | ||
| Assets | $23.3M | |
| Equity | -$4.8M | -$862.0K |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $10.9M | $15.5M |
| Total Cash Paid And Received | ||
| Purchase Of Property Plant And Equipment Classified As Investing Activities | ||
| Cash Flows From Used In Operating Activities | ||
| Cash Flows From Used In Investing Activities | ||
| Adjustments For Decrease Increase In Trade And Other Receivables | ||
| Cash Flows From Used In Financing Activities | ||
| Cash And Cash Equivalents At Carrying Value | $10.8M | $15.4M |
| Adjustments For Increase In Liability With Respect To Loans From Others | ||
| Adjustment In Depreciation Of Property Plant And Equipment And Rightofuse Assets | ||
| Total Changes In Asset And Liability | ||
| Decrease Increase In Other Longterm Assets | ||
| Adjustments For Increase Decrease In Employee Benefit Liabilities | ||
| Restricted Cash | $127.0K | $140.0K |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | -$3.3M | -$2.0M |
| Trade And Other Current Receivables | ||
| Trade And Other Current Payables | ||
| Retained Earnings | ||
| Property Plant And Equipment | ||
| Other Payables Current | ||
| Noncurrent Liabilities | ||
| Noncurrent Assets | ||
| Equity And Liabilities | ||
| Current Liabilities | ||
| Current Assets | ||
| Retained Earnings Accumulated Deficit | -$119.4M | |
| Property Plant And Equipment Net | $10.8M | |
| Other Loans Payable Long Term | $21.9M | |
| Operating Lease Right Of Use Asset | $1.4M | |
| Operating Lease Liability Noncurrent | $1.0M | |
| Liabilities Noncurrent | $25.5M | |
| Liabilities Current | $2.6M | |
| Liabilities And Stockholders Equity | $23.3M | |
| Increase In Liability With Respect To Government Grants |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | -$2.0M | $575.0K | $1.7M | -$4.4M | $827.0K | -$2.9M | -$299.0K | $415.0K | ||
| Increase Decrease In Trade Payables And Other Accounts Payables | -$1.2M | $15.2M | $3.7M | -$14.5M | -$5.5M | $238.0K | -$415.0K | |||
| Increase Decrease In Cash And Cash Equivalents | $14.3M | -$63.0M | -$3.4M | $4.5M | $55.7M | -$17.8M | $23.9M | |||
| Share Based Compensation | $682.0K | $1.1M | $1.6M | $2.8M | ||||||
| Payments To Acquire Property Plant And Equipment | $12.0K | $637.0K | $836.0K | $139.0K | ||||||
| Net Cash Provided By Used In Operating Activities | -$6.3M | -$9.4M | -$7.3M | -$7.4M | ||||||
| Net Cash Provided By Used In Investing Activities | -$12.0K | -$637.0K | -$836.0K | -$139.0K | ||||||
| Increase Decrease In Other Accounts Payable | $157.0K | -$341.0K | $309.0K | $644.0K | ||||||
| Increase Decrease In Operating Lease Liability | -$314.0K | -$58.0K | -$156.0K | -$150.0K | ||||||
| Increase Decrease In Accounts Payable Trade | -$156.0K | -$150.0K | -$175.0K | $3.0K | ||||||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | -$9.0K | -$272.0K | -$2.0M | $575.0K | ||||||
| Net Cash Provided By Used In Financing Activities | $3.4M | $1.1M | $6.8M | $21.4M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q1 2023 | Q1 2022 |
|---|---|---|
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | ||
| Increase Decrease In Trade Payables And Other Accounts Payables | ||
| Increase Decrease In Cash And Cash Equivalents | ||
| Share Based Compensation | $252.0K | $485.0K |
| Payments To Acquire Property Plant And Equipment | $6.0K | $521.0K |
| Net Cash Provided By Used In Operating Activities | -$3.1M | -$1.1M |
| Net Cash Provided By Used In Investing Activities | -$6.0K | -$521.0K |
| Increase Decrease In Other Accounts Payable | -$369.0K | $79.0K |
| Increase Decrease In Operating Lease Liability | $7.0K | -$62.0K |
| Increase Decrease In Accounts Payable Trade | $629.0K | $311.0K |
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | -$224.0K | -$359.0K |
| Net Cash Provided By Used In Financing Activities |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Weighted Average Number Of Diluted Shares Outstanding | 3.23B | 1.56B | 754.1M | 564.6M | ||||||
| Earnings Per Share Diluted | $0.00 | $0.01 | $-0.02 | |||||||
| Earnings Per Share Basic | $0.00 | $0.01 | $-0.02 | |||||||
| Weighted Average Shares | 564.6M | 443.3M | 326.7M | 261.4M | 201.0M | 135.1M | 105.5M | |||
| Weighted Average Number Of Shares Outstanding Basic | 1.56B | 754.1M | 564.6M | |||||||
| Common Stock Shares Outstanding | 3.41B | 1.86B | 989.3M | 739.0M | ||||||
| Common Stock Shares Issued | 3.41B | 1.86B | 989.3M | 739.0M | ||||||
| Common Stock Shares Authorized | 40.00B | 20.00B | 20.00B | 1.80B |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q1 2023 | Q1 2022 |
|---|---|---|
| Weighted Average Number Of Diluted Shares Outstanding | 1.30B | 744.7M |
| Earnings Per Share Diluted | $0.00 | $0.00 |
| Earnings Per Share Basic | $0.00 | $0.00 |
| Weighted Average Shares | ||
| Weighted Average Number Of Shares Outstanding Basic | 1.30B | 744.7M |
| Common Stock Shares Outstanding | 1.31B | |
| Common Stock Shares Issued | 1.31B | |
| Common Stock Shares Authorized | 20.00B |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|
| Finance Costs | $3.5M | $15.6M | $30.8M | $13.6M | $10.9M | $303.0K | $24.0K |
| Adjustments For Sharebased Payments | $2.9M | $9.5M | $3.7M | $260.0K | $519.0K | $1.3M | $745.0K |
| Adjustments For Finance Income Cost | $930.0K | -$12.9M | -$15.9M | $2.1M | -$10.9M | ||
| Increase Decrease Through Sharebased Payment Transactions | $69.0M | $70.3M | $260.0K | $519.0K | $1.3M | $745.0K | |
| Interest Paid Classified As Operating Activities | $11.0K | $45.0K | $131.0K | $46.0K | $73.0K | $27.0K | $23.0K |
| Share Premium | $388.1M | $310.2M | $255.3M | $179.9M | $179.7M | $113.0M | |
| Noncurrent Provisions For Employee Benefits | $31.0K | $95.0K | $89.0K | $82.0K | $83.0K | $76.0K | |
| Interest Received Classified As Operating Activities | $2.0K | $2.0K | $98.0K | $13.0K | $62.0K | $18.0K | |
| Finance Income | $5.7M | $3.8M | $4.0K | $2.9M | $18.0K | $3.0M | $1.1M |
Most recent annual filing with the SEC: May 7, 2025
Data sourced from SEC EDGAR public filings as of August 5, 2026.